Abstract
Background -The aim of this study was to evaluate the effects ofsingle and chronic dosing with salmeterol on exercise capacity and lung function in patients with chronic obstructive pulmonary disease. Methods -Twenty nine patients of mean (SE) age 64 ( 1.5) years, forced expiratory volume in one second (FEVy) 42(3)% of predicted, and 5-15% reversibility to salbutamol 200 tg were randomised to receive four weeks treatment with salmeterol 50 Ftg twice daily or placebo in a double blind crossover fashion with a one week washout period in between. Measurements ofspirometric parameters, static lung volumes, and exercise capacity were made one and six hours after a single dose, and six hours after the final dose of salmeterol or placebo.
Results -Salmeterol produced a small increase in FEV, at one and six hours after a single dose, and this was maintained after chronic dosing (mean difference and 95% CI versus placebo): single dosing at one hour 0.07(95% CI 0-02 to 0.11) 1, single dosing at six hours 0-16 (95% CI 0 09 to 0.22) 1 , chronic dosing at six hours 0.11(95% CI 0*03 to 0-19) 1 . The increase in forced vital capacity (FVC) was greater with salmeterol than with placebo six hours after single but not chronic dosing: single dosing at six hours 0 17 (95% CI 0 04 to 0.29) 1, chronic dosing at six hours 0-02 (95% CI -0*18 to 0.22) 1 . Slow vital capacity was increased after treatment with salmeterol compared with placebo one and six hours after single but not after chronic dosing. There Assessment of exercise capacity in this group of patients does, however, present difficulties. When evaluating exercise capacity in normal subjects an assessment of maximum oxygen consumption is usually made. This, however, requires repeated estimations to ensure adequate consistency of the measurement, and the procedure itself is demanding because it requires exercise to exhaustion which would be both hazardous and impractical in patients with COPD. Attempts have therefore been made to establish reliable indices of performance during submaximal exercise. Spiro et al suggested the concept of physiological strain.3 By measuring heart rate and ventilation at relatively low levels of oxygen consumption it is possible to relate the increase in heart rate or ventilation to an estimate of the subject's maximum capacity to increase heart rate or ventilation. This capacity for increase is termed the adaptation capacity. Thus, an individual will be less fit and have a greater physiological strain if a given energy expenditure requires a larger proportion of the adaptation capacity. The primary aim of this study was to evaluate the effect of single and chronic dosing with salmeterol on exercise capacity in patients with COPD. The effects of single and chronic dosing with salmeterol on lung function were also assessed.
Methods

SUBJECTS
Patients with stable COPD with a forced expiratory volume in one second (FEV,) of Grove, Lipworth, Reid, Smith, Ramage, Ingram, _Jenkins, Winter, Dhillon 25-75% of predicted normal and 5-15% reversibility to salbutamol 200 ,ug were recruited into the study. Patients with other significant systemic or musculoskeletal disease or those requiring maintenance therapy with oral steroids were excluded.
Forty six patients were initially recruited from a respiratory outpatient clinic of whom 29 were randomised to treatment and were therefore included in the intent-to-treat analysis. Reasons for withdrawal prior to randomisation were as follows: ineligibility (three patients), adverse events (three patients), defaulted (four patients), failure to return (six patients), and non-compliance (one patient). All patients gave written informed consent to participate in the study which was approved by the Tayside committee for medical ethics.
The intent-to-treat population consisted of 22 men and seven women with a mean (SE) age of 64 (1-5) years, FEVy of 1-18 (0 08) 1, 42 (3)% of predicted, and 12.5 (1-3)% reversibility to salbutamol 200 tg. All subjects had a history of current or previous tobacco smoking. Concurrent medication during the study was as follows: inhaled corticosteroids (24 patients), theophylline preparations (six), and inhaled anticholinergics (seven). Prior to the run-in period 28 patients were using inhaled 12 agonists.
Ofthe 29 patients in the intent-to-treat population, 24 completed the study. Reasons for withdrawal after randomisation to treatment were as follows: adverse events (three patients), ineligibility (one), non-compliance (one), and one patient defaulted.
DESIGN
The study was of a randomised, double blind, placebo controlled, crossover design with 15 patients being allocated to receive salmeterol followed by placebo, and 14 patients receiving placebo followed by salmeterol. At the end of the run-in period patients attended the laboratory to receive their first dose of study medication -that is, the randomisation visit. Spirometric tests were performed before the first dose, at regular intervals during the first hour after the first dose, and again six hours after dosing. Static lung volume and gas transfer measurements, six minute walking and cycle ergometry tests were performed one and six hours after the single dose. At the end of the four week treatment period patients attended the laboratory six hours after the final dose of study medication and spirometric tests, static lung function and gas transfer measurements, six minute walking and cycle ergometry tests were then performed. Subjects then had a one week washout period before crossing over to the second treatment period. figure) . Of the 24 patients who completed the study eight were defined as bronchodilator responders with an increase in FEV1 of >160 ml after a single dose of salmeterol, and seven patients fulfilled the criteria after chronic dosing with five fulfilling the criteria after both single and chronic dosing. With regard to FVC, nine patients had an increase of >330 ml after a single dose ofsalmeterol which was maintained in six after chronic dosing; five patients showed the increase after both single and chronic dosing. Only two patients showed a persistent improvement in both FEV, and FVC.
MEASUREMENTS
STATIC LUNG VOLUMES
There were no significant differences in static lung volumes following single or chronic dosing with salmeterol or with placebo (table 1) .
SIX MINUTE WALKING TEST
There was no significant increase in the distance walked six hours after single or 
BICYCLE ERGOMETRY
There were no significant differences in oxygen uptake, ventilation, and heart rate responses or oxygen saturation during exercise following treatment with salmeterol or placebo. In addition, there were no significant differences in derived variables of physiological strain for heart rate and ventilation after treatment with salmeterol or placebo. Treatment with salmeterol was not associated with a reduction in Borg scores following bicycle ergometry compared with placebo (table 2) . during the run-in period and the crossover design of the study would, however, have minimised the influence of such an effect on the results. In patients with COPD exercise limitation may be due to a combination of abnormalities including abnormalities of ventilatory mechanics, respiratory muscles, alveolar gas exchange and cardiac function. '8 Alterations in ventilatory mechanics provide one of the most important limitations to exercise performance. Expiratory airflow obstruction is the main pathophysiological consequence of the underlying disease and, as a result, resting expiratory airflows in the patients in this study would be near to their achievable maximum. The prolongation of expiration together with the increased breathing rate during exercise will lead to hyperinflation and consequently an increase in the work of breathing. Thus, it could be predicted that relieving some of the expiratory obstruction may improve pulmonary mechanics by enabling breathing at a lower residual volume and therefore exercise capacity. In this study the small improvements in spirometric values were not, however, associated with an improvement in exercise capacity. This is perhaps not surprising given that "gas trapping" measured at rest was not significantly improved either in terms of a reduction in residual volume or the ratio of residual volume to total lung capacity.
From a practical point of view this study suggests that relatively complex exercise testing does not provide any additional useful information in terms of detecting clinically relevant improvements compared with more straightforward tests of lung function and six minute walking distance. With the exception of the Borg symptom scores following the six minute walking test, the responses were consistent after both single dosing and a period of regular treatment.
The symptomatic improvement which allows a comparable distance to be walked in six minutes with less perceived exertion after chronic dosing with salmeterol may represent a significant benefit to these patients in whom treatment options are relatively limited. In this regard a more detailed assessment offunctional capacity and quality of life may have provided further evidence of benefit from treatment with salmeterol, as observed in a recent study which evaluated the effects of chronic dosing with salmeterol or placebo on quality of life in patients with COPD."9
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